- Home
- NTIP vs VRCA Comparison
NTIP vs VRCA Comparison
Compare NTIP & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTIP | VRCA |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0M | 32.7M |
| IPO Year | 1998 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NTIP | VRCA |
|---|---|---|
| Price | $1.36 | $8.16 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.4K | ★ 402.7K |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | ★ 7.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $150,000.00 | ★ $30,829,000.00 |
| Revenue This Year | N/A | $373.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 234.73 |
| 52 Week Low | $1.16 | $3.28 |
| 52 Week High | $1.90 | $9.82 |
Technical Indicators
Market Signals| Indicator | NTIP | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 63.93 |
| Support Level | $1.36 | $7.82 |
| Resistance Level | $1.46 | $9.78 |
| Average True Range (ATR) | 0.09 | 1.17 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 25.00 | 67.61 |
Price Performance
Historical ComparisonAbout NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.